OrthoPediatrics Corp. (NASDAQ:KIDS) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) have been given a consensus recommendation of “Moderate Buy” by the ten research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $24.00.

Several brokerages have recently weighed in on KIDS. Citigroup reiterated an “outperform” rating on shares of OrthoPediatrics in a research note on Friday, October 10th. Piper Sandler decreased their price objective on OrthoPediatrics from $30.00 to $22.00 and set an “overweight” rating for the company in a research report on Friday, October 10th. Truist Financial set a $18.00 target price on OrthoPediatrics in a report on Friday, October 10th. Canaccord Genuity Group began coverage on OrthoPediatrics in a research note on Wednesday, December 10th. They set a “buy” rating and a $24.00 price target for the company. Finally, Lake Street Capital lowered their price objective on shares of OrthoPediatrics from $37.00 to $34.00 and set a “buy” rating on the stock in a research report on Friday, October 10th.

OrthoPediatrics Price Performance

Shares of NASDAQ KIDS opened at $17.57 on Friday. The stock has a market cap of $440.66 million, a P/E ratio of -9.01 and a beta of 1.06. OrthoPediatrics has a twelve month low of $15.28 and a twelve month high of $27.60. The stock has a 50 day moving average of $17.44 and a two-hundred day moving average of $19.46. The company has a current ratio of 7.40, a quick ratio of 3.52 and a debt-to-equity ratio of 0.28.

OrthoPediatrics (NASDAQ:KIDS) last announced its earnings results on Monday, January 9th. The company reported ($0.15) EPS for the quarter. The business had revenue of $25.08 million during the quarter. OrthoPediatrics had a negative net margin of 20.06% and a negative return on equity of 6.86%. On average, research analysts forecast that OrthoPediatrics will post -0.93 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. boosted its holdings in OrthoPediatrics by 433.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after purchasing an additional 1,139 shares in the last quarter. Caption Management LLC acquired a new stake in shares of OrthoPediatrics in the 3rd quarter valued at approximately $54,000. BNP Paribas Financial Markets lifted its holdings in shares of OrthoPediatrics by 60.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock valued at $61,000 after buying an additional 1,235 shares during the period. PDT Partners LLC purchased a new stake in shares of OrthoPediatrics in the first quarter valued at approximately $244,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in OrthoPediatrics by 6.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock worth $246,000 after acquiring an additional 645 shares during the period. 69.05% of the stock is owned by hedge funds and other institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.